Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Bucky Katt who wrote (7464)	3/25/2002 2:20:40 PM
From: Catfish	Read Replies (1) \| Respond to of 48461

WS, I am glad you mentioned TRIB. I noticed this a couple of weeks ago, and bought a few shares.

To: Bucky Katt who wrote (7464)	3/25/2002 4:41:12 PM
From: tsigprofit	Read Replies (1) \| Respond to of 48461

GUMM detailed info & more, William. Yes, they sold their gum operations to Wrigley in July 2001. Here is their blurb about their current focus: Gum Tech International, Inc. is an innovative nutrient and drug delivery technology company engaged in the development, manufacture and marketing of delivery systems for bioactive compounds. Gum Tech is the majority owner of Gel Tech LLC, which markets Zicam(TM) Cold Remedy, a patented, revolutionary homeopathic remedy, and Zicam(TM) Allergy Relief, a homeopathic remedy designed to provide relief to allergy sufferers. In a study published in the October 2000 issue of the ENT -- Ear, Nose & Throat Journal, Zicam(TM) Cold Remedy was shown to reduce the duration of the common cold by an average of 75% when taken at the onset of symptoms. For additional information, please contact Lynn Romero, Manager of Investor Relations, 602-252-1617, ext. 320, lromero@gum-tech.com. Gum Tech is located at 246 East Watkins Street, Phoenix, Arizona 85004. I was able to find this also: PHOENIX, Mar 13, 2002 /PRNewswire-FirstCall via COMTEX/ -- Gum Tech International Inc. (GUMM) , developer and distributor of Zicam(R) Cold Remedy and Zicam(R) Allergy Relief, announced today that the cold remedy will be the subject of an upcoming scientific presentation by Sherif Beniameen Mossad, M.D., F.A.C.P., F.I.D.S.A. at the 10th International Congress of Infectious Diseases (ICID) taking place in Singapore this week. During a poster session at the conference, Dr. Mossad, of the Department of Infectious Diseases at the Cleveland Clinic Foundation, will present the results of a new clinical study designed to specifically measure the effects of a zincum gluconicum nasal gel (Zicam Cold Remedy) on patients identified as having rhinovirus. The study results are currently undergoing peer review as a preliminary to possible publication in a professional journal. The study was funded by Gum Tech International, Inc. ******* I'm excited that I got both GUMM and TRIB today. I think they will make good additions to the rat portfolio. Matt